The 73% mean reduction in cerebrospinal fluid tau observed 90 days after the final dose in Arrowhead Pharmaceuticals' Phase 1/2a study supports potential ARO-MAPT dosing once every three months or less frequently.

From the articleExperimental Arrowhead RNAi drug hints at Alzheimer’s benefitAlso in Arrowhead reports positive interim data for Alzheimer’s drug By Investing.com